FDA official logo
GSRS logoPFDA official logo

LONCASTUXIMAB TESIRINE

UNII:7K5O7P6QIU
Formula:
Preferred Substance Name:LONCASTUXIMAB TESIRINE

  • 1879918-31-6
  • ADCT-402
  • IMMUNOGLOBULIN G1, ANTI-(HUMAN CD19 ANTIGEN) (HUMAN-MUS MUSCULUS MONOCLONAL RB4V1.2 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL RB4V1.2 .KAPPA.-CHAIN, DIMER, BIS(THIOETHER) WITH N-(31-(2,5-DIHYDRO-2,5-DIOXO-1H-PYRROL-1-YL)-1,29-DIOXO-4,7,10,13,16,19,22,25-OCTAOXA-28-AZAHENTRIACONT-1-YL)-L-VALYL-N-(4-(((((11S,11AS)-8-((5-(((11AS)-5,11A-DIHYDRO-7-METHOXY-2-METHYL-5-OXO-1H-PYRROLO(2,1-C)(1,4)BENZODIAZEPIN-8-YL)OXY)PENTYL)OXY)-11,11A-DIHYDRO-11-HYDROXY-7-METHOXY-2-METHYL-5-OXO-1H-PYRROLO(2,1-C)(1,4)BENZODIAZEPIN-10(5H)-YL)CARBONYL)OXY)METHYL)PHENYL)-L-ALANINAMIDE
  • IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS B-LYMPHOCYTE ANTIGEN CD-19)CHIMERIC MONOCLONAL ANTIBODY CONJUGATED TO AN AVERAGE OF TWO MOLECULES OF TESIRINE.GAMMA.1 HEAVY CHAIN (1-449) (MUS MUSCULUS VH (IGHV1-69*02 (86%) (IGHD)-IGHJ4*01)) (8.8.13) (1-120) -HOMO SAPIENS IGHG1*03 ((R97)CH1(K>R(217)),DES-K107CH3(K>-(250))), (121-249)) (223-211')-DISULFIDE WITH .KAPPA. LIGHT CHAIN (1'-211') (MUS MUSCULUS V-KAPPA (IGKV4-70*01 (91%) IGKJ1*01) (5.3.7) (1'-104') -HOMO SAPIENS IGKC*01 (105'-211')), DIMER (229-229'':232-232'')-BISDISULFIDE, AN AVERAGE OF TWO CYSTEINES ARE S-LINKED TO (111AS,911S,911AS,16S,19S,523RS)-911-HYDROXY-17, 97-DIMETHOXY-12,92,16-TRIMETHYL-15,95,10,15,18,21,49,522-525-NONAOXO-19-(PROPAN-2-YL)-15,111A,911,911A-TETRAHYDRO-11H,91H,95H-2,8,11,24,27,30,33,36,39,42,45-UNDECAOXA-14,17,20,48-TETRAAZA-1(8),9(8,10)-BIS(PYRROLO(2,1-C)(1,4)BENZODIAZEPINE)-52(1)-PYRROLIDINA-13(1,4)BENZENADOPENTACONTAPHAN-523-YL
  • LONCASTUXIMAB TESIRINE [INN]
  • LONCASTUXIMAB TESIRINE [USAN]
  • LONCASTUXIMAB TESIRINE [WHO-DD]
  • LONCASTUXIMAB TESIRINE LPYL [WHO-DD]
  • LONCASTUXIMAB TESIRINE-LPYL
  • ZYNLONTA




UNII - 7K5O7P6QIU | UNII Search Service